JESÚS FERNANDO
SAN MIGUEL IZQUIERDO
Investigador no período 1986-2013
Charité
Berlín, AlemaniaPublicacións en colaboración con investigadores/as de Charité (5)
2023
2022
-
Corrigendum to “OAB-005: Update of safety and efficacy of Isatuximab short-duration fixed-volume infusion plus Bortezomib, Lenalidomide, and Dexamethasone combined therapy for NDMM ineligible/with no immediate intent for ASCT” [Clinical Lymphoma Myeloma and Leukemia 21 S2 (2021) S3-S4](S2152265021X00122)
Clinical Lymphoma, Myeloma and Leukemia
2013
-
Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma
Journal of Clinical Oncology
2009
-
The use of bisphosphonates in multiple myeloma: Recommendations of an expert panel on behalf of the European Myeloma Network
Annals of Oncology, Vol. 20, Núm. 8, pp. 1303-1317
2008
-
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
Leukemia, Vol. 22, Núm. 2, pp. 414-423